TherapeuticsMD, Inc. (TXMD)

NASDAQ: TXMD · IEX Real-Time Price · USD
3.86
+0.27 (7.52%)
At close: Mar 24, 2023, 4:00 PM
3.71
-0.15 (-3.89%)
After-hours: Mar 24, 2023, 7:34 PM EDT
7.52%
Market Cap 36.54M
Revenue (ttm) 87.49M
Net Income (ttm) -8.67M
Shares Out 9.47M
EPS (ttm) -1.43
PE Ratio n/a
Forward PE 2.29
Dividend n/a
Ex-Dividend Date n/a
Volume 59,757
Open 3.59
Previous Close 3.59
Day's Range 3.44 - 3.90
52-Week Range 1.99 - 21.00
Beta 1.19
Analysts Buy
Price Target 5.10 (+32.12%)
Earnings Date Mar 30, 2023

About TXMD

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR... [Read more]

Sector Healthcare
CEO Robert Finizio
Employees 416
Stock Exchange NASDAQ
Ticker Symbol TXMD
Full Company Profile

Financial Performance

In 2021, TherapeuticsMD's revenue was $86.95 million, an increase of 34.03% compared to the previous year's $64.87 million. Losses were -$172.42 million, -6.05% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for TXMD stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 32.12% from the latest price.

Price Target
$5.1
(32.12% upside)
Analyst Consensus: Buy
Stock Forecasts

News

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced that it has com...

2 months ago - Business Wire

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced that it has ent...

3 months ago - Business Wire

TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

TherapeuticsMD Announces Third Quarter 2022 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the third qu...

4 months ago - Business Wire

TherapeuticsMD Announces Additional $7 Million Private Placement

BOCA RATON, Fla.

5 months ago - Business Wire

TherapeuticsMD Announces $7 Million Private Placement

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women's healthcare company, announced today that it received a $7 mil...

6 months ago - Business Wire

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women's healthcare company, announced today the appointment of Dr. Br...

6 months ago - Business Wire

TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

TherapeuticsMD Announces Second Quarter 2022 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the Second Qua...

7 months ago - Business Wire

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its second quar...

8 months ago - Business Wire

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women's healthcare company, announced today that it has received a $1...

8 months ago - Business Wire

Why TherapeuticsMD Shares Are Sinking Today?

Women's healthcare company TherapeuticsMD Inc (NASDAQ: TXMD) shares are falling as EW Healthcare Partners did not acquire the required majority of shares of TXMD through the previously announced tende...

9 months ago - Benzinga

TherapeuticsMD's stock falls 41% after tender offer expires

Shares of TherapeuticsMD Inc. TXMD, +8.67% tumbled 41.6% in premarket trading on Wednesday after the women's health company told investors that EW Healthcare Partners' planned acquisition of Therapeut...

9 months ago - Market Watch

TherapeuticsMD Announces Expiration of Tender Offer

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TXMD” or the “Company”) an innovative, leading women's healthcare company, announced today that Athene Merger, Inc., an affili...

9 months ago - Business Wire

EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer

TherapeuticsMD has previously stated that absent the successful closing of this transaction, the Company would likely be required to file for protection under Chapter 11. BOCA RATON, Fla.

9 months ago - PRNewsWire

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Other symbols: ELYMWEBR
9 months ago - Benzinga

5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Other symbols: BEEMELYMISIGJOAN
10 months ago - Benzinga

EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD

NEW YORK , June 6, 2022 /PRNewswire/ -- EW Healthcare Partners (together with its consolidated subsidiaries and affiliates "EW") announced today that its affiliate, Athene Merger Sub, Inc. ("Purchaser...

10 months ago - PRNewsWire

Investor Alert - The M&A Class Action Firm Announces an Investigation of TherapeuticsMD, Inc. - TXMD

NEW YORK , June 1, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rat...

10 months ago - PRNewsWire

THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TherapeuticsMD, ...

10 months ago - Business Wire

SHAREHOLDER ALERT: Weiss Law Investigates TherapeuticsMD, Inc.

NEW YORK , May 31, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of TherapeuticsMD, Inc. ("TherapeuticsMD" o...

10 months ago - PRNewsWire

Here is why TherapeuticsMD jumped 300%

TherapeuticsMD Inc. (NASDAQ: TXMD) surged 300% after the women's healthcare firm announced the signing of a definitive agreement to be purchased by an EW Healthcare Partners affiliate. EW Healthcare P...

10 months ago - Invezz

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TherapeuticsMD, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - May 31, 2022) - Rigrodsky Law, P.A. is investigating TherapeuticsMD, Inc. ("TXMD") (NASDAQ: TXMD) regarding possible breaches of fiduciary duties and other viol...

10 months ago - Newsfile Corp

Why Is TherapeuticsMD (TXMD) Stock Up 360% Today?

TherapeuticsMD (TXMD) stock is rocketing higher on Tuesday following news of an acquisition deal with EW Healthcare Partners. The post Why Is TherapeuticsMD (TXMD) Stock Up 360% Today?

10 months ago - InvestorPlace

Shareholder Alert: Ademi LLP investigates whether TherapeuticsMD, Inc. has obtained a Fair Price in its transaction with EW Healthcare

MILWAUKEE , May 31, 2022 /PRNewswire/ -- Ademi LLP is investigating TherapeuticsMD (NASDAQ: TXMD) for possible breaches of fiduciary duty and other violations of law in its transaction with EW Healthc...

10 months ago - PRNewsWire